Anavex Life Sciences Corp (AVXL)

[frrol]

Author rightly focused on the table/chart discrepancies and blot duplicates, and noted the company didn't actually clear anything up and that this is "troubling". Instead of ripping off the bandage, the company is obfuscating and that's gonna drag their pain out. They'll probably find they have to do yet another public "response" (third time the charm?) whether they want to or not. At the very least they'll have to be forthcoming with the FDA and in their next 10Q.

But some important context: these presentation problems were just in the biomarker study. Their other ongoing study is open label efficacy, and that was positive at the 9 month interim with 50 patients, and no apparent presentation flaws. There was potential signal (stat sig) of improvement in ADAS-Cog over SOC for 88% of patients, with 66% improving over baseline. The interim n was bigger than our open label phase 2A, and it's ultimately n=150. You can see how this company got the market's attention in AD.

I think our controlled PDD and low-dose Rett studies are more credible, and combined with our small AD 2A and broad MOA and strong pre-clinical support it all shows a potentially superior drug and future outcome. We're just not as closely identified with the higher profile AD indication as SAVA is. I suspect that is changing over time.